---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-098205"
form_type: "8-K"
ticker: "INM"
cik: "0001728328"
company_name: "InMed Pharmaceuticals Inc."
filed_at: "2025-10-14T23:59:59+00:00"
generated_at: "2026-05-17T03:55:27.284642+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# InMed appoints Neil Klompas to board, effective October 9, 2025

## Summary
- Neil Klompas, CPA, CA, appointed to Board; board size increased to 5 members.
- Klompas brings 30+ years experience; was President/COO and CFO at Zymeworks (NASDAQ: ZYME), led 2017 IPO.
- Currently CEO of Augerex Life Science Corp, serves on boards of NervGen Pharma (TSXV: NGEN) and HTuO Biosciences.
- He will receive standard non-employee director compensation: US$50k annual retainer plus potential committee fees.
- No related party transactions or family relationships with any director or officer.

## SEC filing metadata
- accession: 0001213900-25-098205
- form_type: 8-K
- ticker: INM
- cik: 0001728328
- company_name: InMed Pharmaceuticals Inc.
- filed_at: 2025-10-14T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1728328/000121390025098205/0001213900-25-098205-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1728328/000121390025098205/ea0260877-8k_inmed.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-098205
- JSON: https://secwatch.observer/filing/0001213900-25-098205.json
- Plain text: https://secwatch.observer/filing/0001213900-25-098205.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.